Combination therapy with HCV protease inhibitor, SCH 503034, plus PEG-intron in hepatitis C genotype-1 PEG-intron non-responders.

Trial Profile

Combination therapy with HCV protease inhibitor, SCH 503034, plus PEG-intron in hepatitis C genotype-1 PEG-intron non-responders.

Completed
Phase of Trial: Phase I

Latest Information Update: 29 Oct 2009

At a glance

  • Drugs Boceprevir; Peginterferon alfa-2b
  • Indications Hepatitis C
  • Focus Adverse reactions; Pharmacodynamics; Therapeutic Use
  • Sponsors Schering-Plough
  • Most Recent Events

    • 29 Oct 2009 Substudy results assesing antiretroviral resistance presented at the 60th Annual Meeting of the American Association for the Study of Liver Diseases.
    • 08 Dec 2008 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top